Please rotate your screen
apply for a license

Innovative technology

HUB Organoid Technology is based on the ground-breaking discovery of Lgr5+ stem cells in the adult intestine by the Hans Clever´s lab¹, which subsequently led to the development of the fist “mini-gut in a dish”². HUB Organoid Technology does not require reprogramming or transformation of stem cells, therefore enabling the development of diseased as well as healthy organoids which preserve the original tissue genetic and epigenetic make up, including clinically-relevant mutations.

Our protocols have been developed, optimized, and standardized for a range of organs and disease types to allow the development of living biobanks of patient-derived organoids that are stable in long-term culture, can be expanded and cryopreserved for multiple applications.

  1. Barker et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449:1003–1007.
  2. Sato et al., Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459:262-265.

Unique patient-relevant models

HUB Organoids™ are developed directly from patient material thanks to our exclusive IP-protected technology that allows adult stem cells (ASCs) present in most epithelial tissues to replicate and differentiate in vitro giving rise to functional “mini-organs in a dish”.

infographic-01-white-technology.png

Applications

  • In vitro disease modelling: capture disease relevance and heterogeneity of the patient population
  • Drug discovery and development: test drug efficacy and investigate your compound´s mechanism of action
  • Clinical Trials in a Dish (CTiD): derisk and expedite your therapeutic development with translational models that can be used to identify your target patient population before entering the clinic
  • Companion diagnostics: identify predictive biomarkers of therapeutic outcome using models that recapitulate original patient pathophysiology
  • Safety and toxicity: evaluate your compound´s safety and toxicity profiles with the only patient-derived in vitro model that can be developed from non-transformed cells residing in healthy epithelia
  • Personalized medicine: leverage HUB Organoids™ as patient avatars to design targeted and personalized therapies and stratify your patient population.

Key features of HUB Organoids™

HUB Organoids are innovative models derived directly from adult stem cells (ASC) present in all epithelial organs. This is an important distinction which sets HUB Organoids apart from other patient-derived 3D in vitro systems or other organoid technologies using pluripotent stem cells (iPSC) or embryonic stem cell (ESC).

HUB Organoids are:

  • Clinically-relevant: derived directly from patient tissue, thus recapitulating the pathophysiology of the parental organ in vivo
  • Tissue-specific: highly specialized for their tissue of origin, e.g. colon stem cells can only produce colon organoids
  • Physiologically relevant: encompassing multiple differentiated and functional cellular lineages, allowing to model healthy and diseased tissue biology
  • Genetically and phenotypically stable in long term culture: maintaining parental tissue characteristics indefinitely in culture and after cryopreservation
  • Expandable for large-scale screens
  • Suitable for genetic manipulation as well as most standard in vitro assays
  • Amenable to in vivo modelling via engraftment or xenotransplantation
infographic-02.png

Want to know more?

Please contact us at +31 (0)88 12 36 300 or email us info@huborganoids.nl or drop us a message via the button below.

contact us
  • Yalelaan 62
  • 3584 CM Utrecht
  • The Netherlands